Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14480242 | 0.86 | L3MBTL1 (0.43) | MAPK1L3MBTL1ALDH1A1MAPTRAB9A | |
| SCHEMBL31003231 | 0.86 | L3MBTL1 (0.43) | MAPK1L3MBTL1ALDH1A1MAPTRAB9A | |
| SCHEMBL2382926 | 0.85 | MAPK1 (0.54) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL22912516 | 0.85 | CA12 (0.53) | MAPK1L3MBTL1ALDH1A1CA1CA2 | |
| SCHEMBL29695095 | 0.84 | MAPK1 (0.61) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL1441132 | 0.84 | MAPK1 (0.61) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL204895 | 0.84 | MAPK1 (0.61) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 | |
| SCHEMBL1680993 | 0.84 | MAPT (0.53) | MAPK1KDM4EL3MBTL1ALDH1A1MAPT | |
| SCHEMBL3950709 | 0.83 | BAZ2B (0.49) | MAPTKMT2AMEN1GABRA5TSHR | |
| SCHEMBL206067 | 0.83 | MAPK1 (0.51) | MAPK1KDM4EL3MBTL1ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| US-20240229063-A1 | TRANSGENIC CORN EVENT ZM_CSM63715 AND METHODS FOR DETECTION AND USES THEREOF | MONSANTO TECHNOLOGY LLC (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118084800-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084801-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112312913-B | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4329881-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117642404-A | Small molecule modulators of glucocerebrosidase activity and uses thereof | 凡况生化公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023161172-A1 | SUBSTITUTED N-BENZOIC ACID URACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | WO | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026904-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026917-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | HONGU MITSUYA | 2010-10-07 | — | — | US | disclosed |
| US-7759373-B2 | Large conductance calcium-activated K channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7553845-B2 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2009-06-30 | — | — | US | disclosed |
| US-20060199962-A1 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2006-09-07 | — | — | US | disclosed |
| US-20040127527-A1 | Large conductance calcium-activated k channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1432690-A2 | IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE | Tanabe Seiyaku Co., Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| WO-2002083111-A2 | IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE | TANABE SEIYAKU CO., LTD. (JP) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | KCNN3, KCNN2, KCNN1 | MAPK1 1386/4885KDM4E 801/4885L3MBTL1 3792/4885 |
| US-20040127527-A1 | Large conductance calcium-activated k channel opener | KCNN1, KCNN4, KCNN3 | MAPK1 1008/4885KDM4E 687/4885L3MBTL1 4076/4885 |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | MAPK1 2880/4885KDM4E 3762/4885L3MBTL1 3828/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MAPK1 4304/4885KDM4E 2853/4885L3MBTL1 3366/4885 |
| US-20060199962-A1 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | FGF1, FGF2, FGFR1 | MAPK1 173/4885KDM4E 1804/4885L3MBTL1 4873/4885 |
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | PFAS, DDT, NOTUM | MAPK1 2350/4885KDM4E 892/4885L3MBTL1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.